Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

This is the authors' abstract. We don't add key points for this paper.

The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance.